IRIS

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)

CASRN 121-82-4

IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Preliminary Assessment Materials)

Notice - This site contains archived material(s).

Archive disclaimer
Archived files are provided for reference purposes only. The file was current when produced, but is no longer maintained and may now be outdated. Persons with disabilities having difficulty accessing archived files may contact the NCEA Webmaster for assistance. Please use the contact form if you need additional assistance.

Overview

In August 2013, EPA released the draft literature searches and associated search strategies, evidence tables, and exposure response arrays for RDX to obtain input from stakeholders and the public prior to developing the draft IRIS assessment. Specifically, EPA was interested in comments on the following:
  • Draft literature search strategies
    • The approach for identifying studies
    • The screening process for selecting pertinent studies
    • The resulting list of pertinent studies
  • Preliminary evidence tables
    • The process for selecting studies to include in evidence tables
    • The quality of the studies in the evidence tables
The literature search strategy, which describes the processes for identifying scientific literature, contains the studies that EPA considered and selected to include in the evidence tables. The preliminary evidence tables and exposure-response arrays present the key study data in a standardized format. The evidence tables summarize the available critical scientific literature. The exposure-response figures provide a graphical representation of the responses at different levels of exposure for each study in the evidence table.

Citation

U.S. EPA. IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Preliminary Assessment Materials). U.S. Environmental Protection Agency, Washington, DC, EPA/635/R-13/140, 2013.

Contact

Louis J. D'Amico,  Ph:  202-564-4605,  Email: damico.louis@epa.gov

Top of Page

Background

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX, or Royal Demolition eXplosive) is a military explosive with limited civilian uses. In the United States, RDX is produced at Army ammunition plants; it is not produced commercially.

An oral reference dose (RfD) and an oral cancer slope factor are currently available on IRIS. A reassessment of the human health effects of RDX, including both cancer effects and effects other than cancer, is being undertaken.

Additional Information

Top of Page

Download(s)

This download(s) is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy.

Federal Register Notices

Docket

Comments on the assessment may be submitted and reviewed using the Docket ID EPA-HQ-ORD-2013-0430

Top of Page